Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study by Mooghali M, Ross JS, Kadakia KT, Dhruva SS

Get full text

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE by Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, A, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Collins, GS, Dawoud, D, Offringa, M, Ouwens, M, Ross, JS, Taylor, RS, Ciani, O

Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators by Ross JS, Bates J, Parzynski CS, Akar JG, Curtis JP, Desai NR, Freeman JV, Gamble GM, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Normand SLT, Ranasinghe I, Shaw RE, Krumholz HM

Get full text

Electron acceleration in laboratory-produced turbulent collisionless shocks by Swadling, GF, Grassi, A, Rinderknecht, H, Higginson, DP, Ryutov, DD, Bruulsema, C, Drake, RP, Funk, S, Glenzer, S, Gregori, G, Li, CK, Pollock, BB, Remington, BA, Ross, JS, Rozmus, Sakawa, Y, Spitkovsky, A, Wilks, S, Park

Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review by Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, AE, Wells, V, Blazeby, J, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Collins, GS, Dawoud, D, Offringa, M, Ouwens, M, Ross, JS, Taylor, RS, Ciani, O

Lorentz mapping of magnetic fields in hot, dense plasmas by Petrasso, R.D., Li, C.K., Seguin, F.H., Rygg, J.R., Frenje, J.A., Betti, R., Knauer, J.P., Meyerhofer, D.D., Amendt, P.A., Froula, D.H., Landen, O.L., Patel, P.K., Ross, J.S., Town, R.P.

Get full text

Time-resolved turbulent dynamo in a laser plasma by Bott, AFA, Tzeferacos, P, Chen, L, Palmer, CAJ, Rigby, A, Bell, AR, Bingham, R, Birkel, A, Graziani, C, Froula, DH, Katz, J, Koenig, M, Kunz, MW, Li, CK, Meinecke, J, Miniati, F, Petrasso, R, Park, H-S, Remington, BA, Reville, B, Ross, JS, Ryu, D, Ryutov, D, Séguin, F, White, TG, Schekochihin, AA, Lamb, DQ, Gregori, G

Laboratory evidence of dynamo amplification of magnetic fields in a turbulent plasma by Tzeferacos, P, Rigby, A, Bott, A, Bell, A, Bingham, R, Casner, A, Cattaneo, F, Churazov, EM, Emig, J, Fiuza, F, Forest, CB, Foster, J, Graziani, C, Katz, J, Koenig, M, Li, CK, Meinecke, J, Petrasso, R, Park, HS, Remington, BA, Ross, JS, Ryu, D, Ryutov, D, White, TG, Reville, B, Miniati, F, Schekochihin, A, Lamb, DQ, Froula, DH, Gregori, G

Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement by Orkin, AM, Gill, PJ, Ghersi, D, Campbell, L, Sugarman, J, Emsley, R, Steg, PG, Weijer, C, Simes, J, Rombey, T, Williams, HC, Wittes, J, Moher, D, Richards, DP, Kasamon, Y, Getz, K, Hopewell, S, Dickersin, K, Wu, T, Ayala, AP, Schulz, KF, Calleja, S, Boutron, I, Ross, JS, Golub, RM, Khan, KM, Mulrow, C, Siegfried, N, Heber, J, Lee, N, Kearney, PR, Wanyenze, RK, Hróbjartsson, A, Williams, R, Bhandari, N, Jüni, P, Chan, A-W

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials by Ciani, O, Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, AE, Blazeby, J, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Dawoud, D, Offringa, M, Ouwens, M, Hróbjartssson, A, Amstutz, A, Bertolaccini, L, Bruno, VD, Devane, D, Faria, CDCM, Gilbert, PB, Harris, R, Lassere, M, Marinelli, L, Markham, S, Powers, JH, Rezaei, Y, Richert, L, Schwendicke, F, Tereshchenko, LG, Thoma, A, Turan, A, Worrall, A, Christensen, R, Collins, GS, Ross, JS, Taylor, RS

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers by Zingg, D, Bhin, J, Yemelyanenko, J, Kas, SM, Rolfs, F, Lutz, C, Lee, JK, Klarenbeek, S, Silverman, IM, Annunziato, S, Chan, CS, Piersma, SR, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, RR, Riedlinger, GM, Ke, H, Madison, R, Drenth, AP, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, MH, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, JR, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, GK, Ross, JS, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, AV, Ali, SM, Burn, TC, Jimenez, CR, Ganesan, S, Wessels, LFA, Jonkers, J